Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
Few people with HIV starting raltegravir and dolutegravir change therapy because of side-effects

Only a few people starting an integrase inhibitor discontinue the treatment during the first year of therapy due to drug-related toxicities, investigators from Switzerland report in an advance

Published
21 July 2017
By
Michael Carter
Proton pump inhibitors may blunt CD4 cell gains, cause immune activation, in people with HIV

Proton pump inhibitors should be used with caution in people with HIV, US researchers say, after finding that people who received long-term treatment for gastric

Published
13 July 2017
By
Keith Alcorn
Medicine information leaflets 'too scary', say experts

A more balanced view of the benefits and potential side effects is being called for in a report.

Published
20 June 2017
From
BBC Health
Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs

Several anecdotal reports of mouth ulcers have recently been reported in people switching to generic abacavir in the UK. This should highlight awareness of the potential of likely-rare new side effects, even when both formulations have been approved as bioequivalent.

Published
23 May 2017
From
HIV i-Base
Life expectancy now near-normal in people with CD4 counts over 350 a year after starting therapy

A large study of 88,504 people with HIV on antiretroviral therapy (ART), published in The Lancet HIV journal and reported widely in the news, has found substantial

Published
15 May 2017
By
Gus Cairns
Switching from efavirenz to lopinavir/ritonavir has no meaningful impact on neurological function, says UK study

Switching from efavirenz does not significantly improve the neurological function of patients taking virologically suppressive antiretroviral therapy, investigators from the UK report in HIV Medicine. The

Published
10 May 2017
By
Michael Carter
Bone density improves in people who switch from tenofovir DF to tenofovir alafenamide

After three years, tenofovir alafenamide (TAF) for first-line HIV treatment was better at suppressing viral load and safer for the bones and kidneys than the older tenofovir

Published
27 March 2017
By
Liz Highleyman
Darunavir Associated with Heart Disease

But atazanavir use in HIV patients not linked to cardiovascular disease.

Published
20 February 2017
From
MedPage Today HIV/AIDS
Tenofovir/emtricitabine/efavirenz less likely to cause adverse birth outcomes than other regimens, Botswana study finds

Infants exposed to an antiretroviral regimen of tenofovir, emtricitabine and efavirenz (Atripla) from conception experienced fewer adverse birth outcomes compared to other three-drug regimens, according to a study

Published
16 February 2017
By
Carole Leach-Lemens
How a gene test can solve side effects linked to ARV drugs in Africa

Studies have shown that people who react particularly badly to efavirenz have a particular gene variant that messes with an enzyme responsible for processing the drug in their bodies.

Published
01 February 2017
From
The Conversation
← First12345...76Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.